VLA — Valneva SE Share News
0.000.00%
Last trade - 00:00- €440.83m
- €529.53m
- €174.66m
France's Valneva 2025 revenue rises, reiterates FY revenue guidance
Brief: Valneva Eyes 2026 Total Revenues OF EUR 155-170 Mln
Brief: EMA's PRAC Warns About Known Risk Of Aseptic Meningitis With Chikungunya Vaccine Ixchiq
Brief: Valneva FY Total Revenues EUR 174.7 Mln
France's Valneva misses 2025 revenue expectations, forecasts lower product sales in 2026
Brief: Valneva Provides Update On Recommendations For Use Of Ixchiq® In United Kingdom
Valneva jumps on 'attractive' risk/reward profile ahead of vaccine's phase 3 results
Brief: Valneva And Instituto Butantan Start Pilot Chikungunya Vaccination Campaign In Brazil
Brief: Valneva Initiates Pilot Vaccination Strategy In Brazil
Valneva shares fall after it withdraws chikungunya vaccine applications in US
French and Benelux stocks-Factors to watch
Valneva withdraws application for standard US approval of its chikungunya shot
Valneva rises after trial data for its chikungunya vaccine in children
Brief: Valneva Reports Positive Phase 2 Results In Children For Chikungunya Vaccine
Brief: Valneva To Further Consolidate Operations In France
Valneva's Lyme vaccine data boosts shares by 7%
Brief: Valneva's Cash, Cash Equivalents At EUR 143.5 Mln At End-September
Brief: Valneva Reports Positive Results For Phase 1 Trial Of Second-Generation Zika Vaccine Candidate
Valneva falls after Lyme disease vaccine data delay, outlook cut